67results about "Sonopheresis" patented technology

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

A method for controlling ultrasonic waves to induced sonoporation of a drug into cancer cells in a tumor. The method may include accessing configuration data that may include a type of the tumor and a type of drug, and determining values of operational parameters that may be based on the configuration data to define determined values. The operational parameters may include frequency value and duty cycle value. The method may also include determining frequency value which may be based on the type of tumor that may define a determined frequency value, and determining the duty cycle value which may be based on the type of drug and the type of tumor that may define a determined duty cycle value.

Methods for enhancing intracellular uptake of active agents by inducing temporary pore formation in a cell membrane are described. The methods generally comprise introducing nanoparticles to a cell in vivo, ex vivo, or in cell culture to magnetic nanoparticles that are taken up into the cell interior. The methods further comprise introducing active agents to the cell. A magnetic field is applied to the cell for targeted excitation of the internalized magnetic nanoparticles to induce temporary pore formation in the cell membrane, such that the active agent is taken up in an increased amount and / or at an increased rate by the cell.

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

Provided herein are methods of treating brain cancer in a subject, comprising evaluating one or more biological samples from a subject who has brain cancer for the presence of a miRNAs and administering interleukin-12 (IL-12); an immunogenic composition of human telomerase reverse transcriptase (hTERT), Wilms Tumor-1 (WT-1), and prostate specific membrane antigen (PSMA); and an anti-programmed cell death receptor 1 (PD-1) antibody to said subject if the subject has an increased expression level of the mIR-331-3p miRNA or isomiRs thereof and the miR-1537-3p miRNA or isomiRs thereof relative to a control population of subjects. Also provided herein are methods of treating brain cancer in a subject, comprising measuring an expression level of at least one mRNA biomarker selected from SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1, HOXD13, TGFβR3, UBA7, SFRP4, or any combination thereof, in a tumor sample from a subject and administering IL-12; an immunogenic composition hTERT, WT-1, and PSMA; and an anti-PD-1 antibody to said subject if the expression level of SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1 and HOXD13 is decreased or if the expression level of TGFβR3, UBA7, SFRP4 is increased.

To provide a vaccine comprising an antigen and IL-21.SOLUTION: Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.SELECTED DRAWING: Figure 1

The present invention, based on a non-bubble-based sonoporation technique, provides an ultrasound-assisted delivery platform for drug-loaded chitosan nanoparticles. This platform comprises: the administration of drug-loaded chitosan nanoparticles and the application of ultrasound stimulation. The drug-loaded chitosan nanoparticles are delivered to a target site, where ultrasound waves are directly applied to induce cellular membrane deformation. The ultrasound mechanical force temporarily alters membrane permeability, thereby facilitating the intracellular delivery of the drug-loaded chitosan nanoparticles.

A method of treating a target tissue area with a ribosome-inactivating protein. The method comprises injecting the target tissue area with an effective dose of a ribosome-inactivating protein and administering electroporation therapy to the target tissue area.

Disclosed are methods of imaging a cancer cell, the method comprising applying a first alternating electric field at a first frequency to the cancer cell for a first period of time, wherein application of the first alternating electric field at the first frequency to the cancer cell for the first period of time increases permeability of cell membranes of the cancer cell; introducing a nanoparticle to the cancer cell, wherein the increased permeability of the cell membranes enables the nanoparticle to cross the cancer cell membrane; and imaging the cancer cell.

A method for monitoring the viability of stem cell-derived cells used in stem cell therapy, comprising: introducing one or more stem cell-derived cells into a cell culture medium; introducing one or more nanoprobes into the cell culture medium, thereby transfecting the one or more stem cell-derived cells with the one or more nanoprobes; and detecting an optical signal from the one or more nanoprobes after transfection. The method may further comprise administering the one or more transfected stem cell-derived cells to a subject and detecting an optical signal from the one or more nanoprobes in vivo. The one or more stem cell-derived cells may comprise stem cells.

The invention discloses a drug delivery microneedle system driven by a miniature ultrasonic patch. The drug delivery microneedle system comprises an excitation circuit, the miniature piezoelectric ultrasonic patch, a drug carrying microneedle array, a coupling structure and a packaging structure. The system has a modulatable sound field characteristic, the excitation circuit drives the piezoelectric ultrasonic patch to generate ultrasonic vibration by applying an electric signal with specific frequency and amplitude, and release of a Janus kinase (JAK) inhibitor loaded by the microneedle array is promoted. The miniature ultrasonic patch adopts a sheet-shaped design, the size is 5-50mm, the thickness is 0.5-5mm, the working frequency is 0.1-4MHz, and the driving voltage is 40-100V. The main body material of the drug-loaded microneedle array is hydrogel capable of loading a JAK inhibitor, the microneedle substrate and the ultrasonic patch are tightly fixed through a coupling structure, and the ultrasonic patch is coated with a packaging structure. The controllability of the drug delivery microneedle is optimized by introducing the modulatable sound field, accurate regulation and control and synergism of drug release can be achieved, and the drug delivery microneedle has important application prospects in targeted therapy of immune skin diseases.

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

Disclosed herein are vaccines comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods can comprise administering the vaccine to the subject in need thereof.

A novel localized, mechanical HIFU (LM-HIFU) transcatheter device that can ablate cancer cells and disrupt the stromal barrier in tumors, enhancing the efficacy of therapeutics and increasing immune cell infiltration. A miniaturized dual-lumen catheter device is configured to deliver M-HIFU to a tumor that does not have the anatomic limitations of conventional HIFU, and enables access to a primary or metastatic tumor regardless of the location.

The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets.

The application provides a targeted drug-loaded microbubble as well as a preparation method and application thereof, and belongs to the technical field of methods for preparing special forms of medicines. The targeted drug-loaded microbubble comprises a PEG shell, a lipid bilayer and a DBCO anchor point, the lipid bilayer is loaded with PTX, the lipid bilayer is located in the PEG shell, and the DBCO anchor point is located on the PEG shell. The targeted drug-loaded microbubble provided by the application can regulate the shape and size of the microbubble, is applied to ultrasonic contrast diagnosis imaging, has excellent targeted killing effect on tumors, and has good biological safety.

The invention belongs to the technical field of biomedicine, and particularly relates to a piezoelectric nanosheet for regulating and controlling distribution and expression of cell membrane protein and a preparation method of the piezoelectric nanosheet. The piezoelectric nanosheet is a bismuth oxyiodate layered nanosheet with an Aurivillius structure, and the surface of the piezoelectric nanosheet is modified by polyvinylpyrrolidone (PVP) and is abbreviated as BIOP; the nanosheet is synthesized by bismuth nitrate pentahydrate, potassium iodate and PVP through a hydrothermal method in one step, and the average size is 93 nm. BIOP can be attached to the surface of a cell, responds to ultrasonic irradiation with different intensities, generates a nanoscale periodic oscillation electric field, and performs electrostatic interaction with charged cell membrane protein on a cell membrane, so that the original hydrophobic force-electrostatic force balance steady state of the membrane protein is broken, internalization and degradation of the membrane protein are efficiently mediated, and regulation and control of distribution and expression of the cell membrane protein are realized. Compared with biochemical strategies such as antagonist drugs, gene editing and the like, the strategy has the unique advantages of being accurate and controllable, high in penetration depth and the like, and has important significance for revealing an intercellular communication mechanism and treating cell membrane protein dependent diseases.

The invention provides a neuroinflammation dual-targeting sound-sensitive liposome as well as a preparation method and application thereof. The neuroinflammation dual-targeting sound-sensitive liposome comprises a liposome, a sound-sensitive agent entrapped in the liposome and an antibody modified on the surface of the liposome, the sound-sensitive agent is benzothiadiazole-triphenylamine, and the structural formula of the sound-sensitive agent is shown in the specification. And the antibody comprises an anti-TMEM119 antibody and an anti-NAT antibody. The neuroinflammation dual-targeting sound-sensitive liposome can target sympathetic neurons and microglial cells at a neuroinflammation part, has a neural immune regulation effect under ultrasonic activation, can be used for preparing a diagnosis and treatment agent for diagnosis and treatment integration of myocardial ischemia reperfusion injury, and realizes diagnosis and treatment integration of myocardial ischemia reperfusion injury.

The present application relates to a DNAzyme nanomaterial synthesis method for treating tumors while maintaining fertility, which first synthesizes DNAzyme with an APE1 enzyme site, then mixes it with hemoglobin, a divalent iron solution and deionized water, forms a nanocomposite through vortexing, centrifuging and washing, and uses tannic acid to achieve encapsulation and preservation during synthesis. The novel nanocomposite synthesized by the present application can dissociate and play a role in tumor cells with high APE1 expression, but not in normal cells, achieving targeted treatment and effectively protecting reproductive organs; at the same time, the novel nanocomposite synthesized through ultrasonic and enzyme double control activation can achieve spatiotemporal controllable combined treatment of tumors, is used for tumor treatment while maintaining fertility, and avoids damage to reproductive organs.

The invention discloses a preparation method and application of a zinc-gallium layered double oxide (ZGPEG) sound-sensitive agent. The preparation method of the ZGPEG sound-sensitive agent is simple and controllable, the overall reaction condition is not harsh, the difficulty of industrial application is low, and the threshold of industrial production is low. Moreover, the ZGPEG material prepared by the preparation method is a sound-sensitive material with narrow-band-gap semiconductor characteristics, and the ZGPEG material shows excellent antibacterial performance in sonodynamic therapy due to the optimized energy band structure and efficient ROS generation capability of the ZGPEG material; and meanwhile, the stable repeatability and the good penetration adaptability provide potential application value for deep bone tissue infection treatment.

The invention discloses a fusion membrane of staphylococcus epidermidis vesicles and turmeric derived exosome-like vesicles as well as a preparation method and application of the fusion membrane. Staphylococcus epidermidis vesicles and turmeric-derived exosome-like vesicles are fused to obtain HMVs, the antibacterial effect of the HMVs is verified through in-vitro experiments, then the HMVs are loaded in hyaluronic acid microneedles, the HMVs MNs nano system can be pressed on acne skin lesions for local administration, and Balb / c mouse in-vivo experiments prove that the HMVs MNs nano system has remarkable antibacterial and anti-inflammatory curative effects. Therefore, the HMVs MNs have good application potential in treating acne.

The present invention provides a pharmaceutical composition for treating obesity, the composition including: one or more viruses selected from the group consisting of yellow fever virus, herpes zoster virus, and rubella virus; or a genetic material coding for a protein derived from these viruses. Preferably, the pharmaceutical composition is a vaccine composition. The composition provides a reduction in target tissues, preferably tissues containing adipocytes, or an effect that leads to the death of adipocytes.

The present application relates to a kind of for anti-infection prodrug and its application. Specifically, the present application provides a meropenem prodrug, the structure of the meropenem prodrug is as shown below. The meropenem prodrug of the present application has excellent therapeutic effect on bacterial biofilm-related infection.

A novel localized mechanical HIFU (LM-HIFU) transcatheter device that can ablate cancer cells and disrupt the stromal barrier in tumors, enhancing efficacy of therapeutic drugs and increasing immune cell infiltration. A miniaturized dual lumen catheter device is configured to deliver M-HIFU to tumors, eliminating the anatomical limitations of conventional HIFU and allowing access to primary or metastatic tumors regardless of their location.

The present disclosure generally relates to technologies for treating cancer, including brain cancers such as a glioblastoma, methods of increasing the concentration of anthracy clines and immune checkpoint modulators in the brain of a subject, and methods of improving use of immune checkpoint modulators in brain cancers. Also disclosed herein are compositions and methods for treating a brain tumor.

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

The present invention relates to a solution for use in electric field ablation of the urinary bladder wall for electroporation of urothelial carcinoma, as well as to a method for electric field ablation of the urinary bladder wall for electroporation of a urothelial carcinoma, in which the solution according to the invention is employed.

Described herein are high-boiling-point-based nanoparticles that release drugs specifically at the focus of ultrasound. The specific conjunction of the high-boiling-point-based nanoparticle formulation with low-frequency ultrasound can be used to deliver therapeutics in a safe and effective manner. The effectiveness and safety of the release is validated in vitro and in non-human primates.

Methods and systems for improving or enabling delivery of antibodies, immunoglobulin receptors, or immunotherapy agents across the Blood-Brain Barrier (BBB) are disclosed. Exosomes are derived from stem cells, immune cell progenitors, or immune cells, and are loaded with an antibody, immunoglobulin receptor, or antibody fragment. Focused energy, preferably low-intensity focused ultrasound, is applied to a region of the BBB of a patient, and loaded exosomes are administered to the patient. Exosomes target the region for delivery of the loaded antibody, receptor, or fragment, either by traversing the BBB at the region or releasing the loaded antibody to neural tissue at the region.

Methods are provided for improving expression of a nucleic acid construct in a cell or organ of a subject using sonoporosis and optimization of the ultrasonic acoustic energy mechanical index.